Our study demonstrates for the first time that platelet-secreted miR-223 via P-MVs can promote lung cancer cell invasion via targeting tumor suppressor EPB41L3.

Study shows that miR223 expression was downregulated in non-small cell lung cancer PC9 leading to the activation of the IGF1R/PI3K/Akt signaling pathway, which may be one mechanism responsible for the resistance to erlotinib.

High miR223 expression is associated with progression of lung cancer.

EGFRAS1 functions as a competitive endogenous RNA (ceRNA) for miR223 to facilitate the expression of IGF1R. The expression of miR223 in human nonsmall cell lung cancer (NSCLC) tissues was negatively correlated with the level of IGF1R. miR-223 is a direct target for EGFRAS1.

Serum miR-223: A Validated Biomarker for Detection of Early-Stage Non-Small Cell lung cancer.

Mortal Obligate RNA Transcript Inhibits cancer Cell Invasion and Migration in lung Adenocarcinoma by Downregulating miRNA-223.